24AUG

$112m for vaccines, none for the wards

4 min read

17:07UTC

CEPI committed $62m across three Bundibugyo vaccine platforms on 1 June and GAVI added $50m, while no treatment was authorised to dose a patient and the outbreak reached an area responders cannot enter.

← Back to Guatemala's measles outbreak outgrew Mexico Jump to analysis ↓

ScienceDeveloping

Key takeaway

Vaccine funding reached $112m the same week no treatment was authorised to dose a single patient.

The Coalition for Epidemic Preparedness Innovations (CEPI), the Oslo-based partnership that finances vaccines for epidemic-threat pathogens, committed $62m on 1 June across three named Bundibugyo platforms: $3.2m for IAVI (the International AIDS Vaccine Initiative) and its rVSV (recombinant vesicular stomatitis virus, a live viral vector carrying an Ebola protein) master seed stock, $50m for a Moderna mRNA candidate through Phase 1, and $8.6m for an Oxford ChAdOx1 vaccine (a chimpanzee adenovirus vector, the platform behind the Oxford COVID jab) manufactured at the Serum Institute of India ¹. GAVI, the Geneva-based Vaccine Alliance, added $50m in procurement contingent on trial success, taking the headline to $112m, atop the roughly $500m pledged at the 26 May Africa CDC summit .

None of that $112m doses a patient in the wards today. WHO advisory groups are still only assessing the MBP134 monoclonal antibody (a lab-made protein engineered to bind and neutralise the virus) and the antiviral remdesivir; neither is authorised to treat a single Bundibugyo case ². No countermeasure has ever been licensed for this non-Zaire species, which is why the assessment continues while patients are treated with supportive care alone.

The outbreak has reached Mambasa, an area of Ituri Province under Islamic State control where health workers cannot safely travel, so contact tracing there is impossible ³. A vaccine months from delivery cannot reach a ward that responders cannot enter, which is why the access gap matters more this month than the funding gap. The money has found the laboratory; it has not found the patient.

Deep Analysis

In plain English

Three companies are now racing to develop a vaccine against this Bundibugyo Ebola strain: Moderna (the mRNA vaccine maker), a team from Oxford University manufacturing through an Indian company called the Serum Institute, and a group using a method called rVSV developed by IAVI. Together they received $112m in funding on 1 June. The catch: even the fastest of these will take 12-18 months to produce doses that have been through proper safety testing. That means no vaccine will be ready while this outbreak is happening now. There are also two experimental treatments , called MBP134 and remdesivir , that could potentially be used on current patients, but neither has yet received regulatory approval to be given to anyone. The money for the future is flowing; the tools for today are still stuck in paperwork.

Deep Analysis

Root Causes

The absence of any approved Bundibugyo countermeasure at PHEIC declaration reflects a market-failure logic in infectious disease R&D: Bundibugyo caused 131 cases in its only prior significant outbreak (2007, Uganda), offering an insufficient commercial return to justify a licensed product.

CEPI was created in 2017 specifically to address this failure by providing public-funding pull for non-commercial pathogens. The current $62m commitment is the system working as designed , but it arrived three weeks into a PHEIC, not three years before it.

Mambasa's IS-controlled access problem creates a second root cause independent of countermeasure availability. Even if MBP134 were authorised today, it could not reach the contact-tracing-inaccessible zones in IS-controlled Ituri: treating the countermeasure gap requires regulatory action, while treating the access gap requires a security intervention that health authorities cannot themselves deliver.

What could happen next?

Opportunity
The Serum Institute of India manufacturing partnership for Oxford's ChAdOx1 candidate establishes an equity-by-design production pathway from Phase 1, avoiding the COVID 2021 scenario where LMIC access was negotiated retrospectively after commercial contracts were already in place.
Medium term · Assessed
Risk
With MBP134 and remdesivir still unauthorised and no approved treatment for Bundibugyo, clinical teams in Ituri face an outbreak measured in hundreds of confirmed cases with supportive care as their only intervention , the same position as 2014 West Africa at outbreak onset.
Immediate · Reported
Precedent
CEPI's framing of the $62m as a 100 Days Mission test case for a non-commercial pathogen establishes a model for public-funded platform investment in pathogens with no prior commercial vaccine development , a potential template for future WHO R&D Blueprint priority pathogens.
Long term · Assessed

Source Landscape

This story draws on neutral-leaning sources

Primary parallel: During the 2018-2020 DRC Kivu outbreak, the merVAC ring-vaccination trial used the rVSV-ZEBOV (Ervebo) vaccine , which IAVI had developed , under a compassionate-use protocol before full regulatory authorisation.

That precedent established the regulatory pathway for using investigational vaccines in active Ebola outbreaks under DRC health ministry protocols. IAVI's rVSV platform position in the current CEPI portfolio echoes that role, but Bundibugyo's rVSV candidate is at seed-stock stage (Phase 0 equivalent), not the Phase 3-ready Ervebo.

Counter-parallel: The 2014-2016 West Africa epidemic began with zero licensed Ebola treatments and ended with WHO deploying ZMapp (an early monoclonal antibody) on a compassionate-use basis before any trial completion.

The lesson drawn was that regulatory frameworks for investigational use in emergencies were too slow , producing the 2019 DRC licensing of Inmazeb and Ebanga. Those approved treatments now cover only Zaire ebolavirus. Bundibugyo repeats the 2014 structural position: active outbreak, investigational-only countermeasures, regulatory clock running.

CEPI's $62m and GAVI's $50m in contingent procurement represent $112m in platform investment, of which the GAVI $50m is conditional on trial success and will not convert to purchased doses within the 2026 response window. For comparison, the Africa CDC/WHO continental plan launched on 5 June requests $518m for 47-country preparedness , a different category of expenditure covering supply chains, training, and rapid response capacity, not research.

The unit economics of the three platforms diverge significantly. Moderna's $50m allocation covers preclinical and Phase 1 for an mRNA candidate that, if authorised, would likely cost $15-25 per dose at non-pandemic pricing. Oxford/SII's $8.6m covers a ChAdOx1 platform that SII can manufacture at $3-5 per dose at scale , the equity differential that drove the COVID AstraZeneca deployment in lower-income countries.

Consensus view: CEPI's 100 Days Mission framework explicitly aims to compress the time from pathogen identification to Phase 1 human dosing to under 100 days. The 1 June commitments , $50m to Moderna's mRNA candidate, $8.6m to Oxford-ChAdOx1 at Serum Institute, $3.2m to IAVI's rVSV seed stock , represent Phase 1 investment, not deployment.

At current outbreak acceleration, no Phase 1 candidate will produce authorised doses before the CDC's August worst-case window. CEPI's approach is correct for long-term preparedness, but provides no countermeasure for this outbreak cohort .

Counter-view: The Serum Institute of India manufacturing partnership carries a structural equity argument that contrasts with the 2021 COVID vaccine distribution failure. Oxford's ChAdOx1 platform was produced at SII for low-income country access during COVID precisely because SII can manufacture at scale and at cost that LMIC procurement systems can afford. Routing the Bundibugyo ChAdOx1 candidate through SII from Phase 1 is earlier equity-by-design than anything attempted in 2021.

Key tension: Whether CEPI's 100 Days Mission framing, which targets future outbreaks, obscures the current treatment gap: the $112m committed buys platform development timelines of 12-18 months, while MBP134 and remdesivir , which could dose patients now , remain unauthorised , and no treatment bridge exists for the 534 patients already confirmed.

First Reported In

Update #6 · Ebola outbreak gets an R0, and a fork

World Health Organization· 9 Jun 2026

Read original →

Causes and effects

Caused by

Donors pledge $500m, 57% over target

CEPI $62m vaccine commitment on 1 June builds on the $500m donor pledge context established at the 26 May Africa CDC summit

Occurred 26 May 2026

Read story →

Only Ebola treatment still cannot dose

MBP134 and remdesivir remaining unauthorised as of 1 June continues the persistent treatment-access gap documented since 29 May

Occurred 1 Jun 2026

Read story →

This Event

$112m for vaccines, none for the wards

The response can mobilise money far faster than access, and a vaccine eight months out cannot reach a ward that health workers cannot safely enter now.

Led to

CEPI funds a fourth Ebola vaccine

The fourth vaccine candidate (Public Health Vaccines rVSV) adds to the three platforms CEPI committed $62m to on 1 June.

Occurred 8 Jun 2026

Read story →

Moderna doses first human in Truro

CEPI's 1 June commitment of $62 million across three Bundibugyo platforms funded the Moderna programme dosed on 3 August.

Occurred 2 Aug 2026

Read story →

Different Perspectives

UK Health Security Agency

UKHSA said egg consumption remains the strongest signal in its 207-case Salmonella Enteritidis investigation. The genomic cluster and 38% hospitalisation among people with available information make exposure identification a public-health priority.

GLEWS+

GLEWS+ assessed spillover risk from clade B MERS in Nile Basin camels as high if the clade establishes, while rating evidence for spread in camel populations low confidence. The joint assessment makes whole-genome sequencing the next test of the threat.

WHO Regional Office for Africa

WHO's Africa office said transmission in DR Congo is outpacing control efforts after laboratory capacity reached 19 sites and treatment capacity exceeded 1,300 beds. The assessment puts access, insecurity, community deaths and late care-seeking ahead of a simple equipment shortage.

People in Guatemala

Guatemala's population now carries the region's largest reported measles burden, with 30,371 confirmed cases and 26 deaths. The scale shifts practical attention from the Mexico-centred frame that followed the World Cup's travel consequences.

Pan American Health Organization

PAHO rated regional measles risk very high after recording 47,459 confirmed cases and 44 deaths through week 28. It names vaccination coverage, accumulated susceptibles and mass gatherings with broad international participation as general risk factors.

Chinese health authorities

China reported three human H9N2 cases to WHO between 10 and 16 July: two four-year-olds recovered, a 44-year-old man remains in intensive care, the first severity signal in a cluster that has produced 173 cases and 2 deaths globally since 2015. The subtype is distinct from the H5N1 series this topic otherwise tracks.